Abstract: The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.
Type:
Grant
Filed:
October 16, 2014
Date of Patent:
September 24, 2019
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Veritech Limited
Inventors:
Dimiter S. Dimitrov, Tianlei Ying, Tina W. Ju, Kwok Yung Yuen
Abstract: The present disclosure provides novel peptides that having immunomodulatory activities in vitro and in vivo. The peptides can include a particular striapathic region of alternating hydrophilic and hydrophobic modules that can adopt an amphipathic conformation under physiological conditions. This disclosure provides peptides that can specifically bind to key functional regions on one or more signaling proteins, particularly pro-inflammatory cytokines, macrophage inhibition proteins, and histone regulation proteins. This disclosure includes peptides that are sufficiently stable in the circulation to allow for intravenous administration. Pharmaceutical compositions including the subject peptides are also provided. The subject peptides find use in methods of modulating macrophage activity. In some cases, the peptide is a CD206-binding agent. Also provided are methods of treating a subject for a condition associated with chronic inflammation using the peptides and compositions of this disclosure.
Type:
Grant
Filed:
August 29, 2018
Date of Patent:
September 17, 2019
Assignee:
Riptide Bioscience, Inc.
Inventors:
Jesse Jaynes, Henry Wilfred Lopez, George R. Martin, Clayton Yates, Charles Garvin
Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions stabilized with an amino acid and suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
Abstract: The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and r
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
April 9, 2019
Assignee:
“SCIENTIFIC CENTER OF ANTI-INFECTIOUS DRUGS” JOINT-STOCK COMPANY
Inventors:
Alexandr Ivanovich Ilin, Murat Esengalievich Kulmanov
Abstract: Provided are methods of treating fibrotic conditions in a subject by the identification of specific subsets of fibrogenic myofibroblasts, such as portal fibroblasts expressing mesothelin, and diagnostic methods useful for determining fibrosis, and the prognosis of fibrosis.
Type:
Grant
Filed:
May 15, 2014
Date of Patent:
March 19, 2019
Assignee:
The Regents of the University of California
Abstract: Non-centrifugal methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The solution rich in IL-1ra can also include at least one of sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1 RII.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
February 19, 2019
Assignee:
Biomet Manufacturing, LLC
Inventors:
Michael D. Leach, Jennifer E. Woodell-May, Joel C. Higgins, Krista O'Shaughnessey
Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.
Type:
Grant
Filed:
August 24, 2016
Date of Patent:
February 12, 2019
Assignee:
TRUSTEES OF BOSTON UNIVERSITY
Inventors:
Nelson Ruiz-Opazo, Victoria L. M. Herrera, Francis Joseph Carr
Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).
Type:
Grant
Filed:
May 23, 2013
Date of Patent:
January 22, 2019
Assignee:
ARGEN-X N.V.
Inventors:
Christophe Blanchetot, Johannes De Haard, Torsten Dreier, Natalie De Jonge, Sebastian Paul Van Der Woning, Nicolas Ongenae
Abstract: The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and r
Type:
Grant
Filed:
December 9, 2011
Date of Patent:
December 11, 2018
Assignee:
“SCIENTIFIC CENTER OF ANTI-INFECTIOUS DRUGS” JOINT-STOCK COMPANY
Inventors:
Alexandr Ivanovich Ilin, Murat Esengalievich Kulmanov
Abstract: Slow vascularization of functional blood limits the transplantation of tissue constructs and the recovery of ischemic and wounded tissues. Blood vessel ingrowth into polysaccharide-based hydrogel scaffolds remains a challenge. A synergistic effect of multiple angiogenic GFs was established; the co-encapsulation of VEGF plus other growth factors induced more and larger blood vessels than any individual GF, while the combination of all GFs dramatically increased the size and number of newly formed functional vessels. Rapid, efficient, and functional neovascularization may be achieved.
Abstract: A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.
Type:
Grant
Filed:
June 11, 2014
Date of Patent:
November 27, 2018
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Yoram Vodovotz, Alexey Solovyev, David Okonkwo, Maxim Mikheev, Qi Mi, Jorg Gerlach, Gregory M Constantine
Abstract: This document provides methods and materials for generating CD8? T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide. For example, methods and materials for using a polypeptide consisting of an SLAFLPESFD amino acid sequence in vivo or in vitro to generate CD8+ T cells having the ability to recognize and lyse cancer cells expressing a HER2/neu polypeptide are provided.
Type:
Grant
Filed:
November 13, 2017
Date of Patent:
November 6, 2018
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias.
Type:
Grant
Filed:
October 2, 2009
Date of Patent:
October 23, 2018
Assignees:
VIB VZW, Life Sciences Research Partners VZW
Abstract: The invention provides compositions and methods for targeting CCR10 and/or the CCR10/ligand axis to modulate the immune response in a subject.
Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anto-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.
Type:
Grant
Filed:
June 4, 2015
Date of Patent:
August 7, 2018
Assignee:
TRUSTEES OF BOSTON UNIVERSITY
Inventors:
Nelson Ruiz-Opazo, Victoria L. M. Herrera
Abstract: A method includes a step of identifying a subject in need of diet modification; and administering a first diet to the subject for a first time period. The first diet provides 4.5 to 7 kilocalories per pound of subject for a first day and 3 to 5 kilocalories per pound of subject per day for a second to fifth day of the first diet. The first diet includes less than 30 g of sugar on the first day; less than 20 g of sugar on the second to fifth days; less than 28 g of proteins on the first day; less than 18 g of proteins on days the second to fifth days; 20 to 30 grams of monounsaturated fats on the first day; 10 to 15 grams of monounsaturated fats on the second to fifth days; and between 6 and 10 grams of polyunsaturated fats on the first day.
Type:
Grant
Filed:
October 22, 2013
Date of Patent:
July 10, 2018
Assignee:
UNIVERSITY OF SOUTHERN CALIFORNIA
Inventors:
Valter D. Longo, Chia-Wei Cheng, Sebastian Brandhorst, Min Wei
Abstract: Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer.
Type:
Grant
Filed:
October 26, 2015
Date of Patent:
June 12, 2018
Assignee:
Genentech, Inc.
Inventors:
Shelly Pizarro, Ailen Sanchez, Charles H. Schmelzer